GLUE Monte Rosa Therapeutics, Inc.

$14.39 +1.12%

Updated 16 d ago

Healthcare · Biological Products, (No Diagnostic Substances)

Monte Rosa Therapeutics, Inc. (GLUE) is a healthcare company in the Biological Products, (No Diagnostic Substances) industry, with a market capitalization of $1.2 billion. Shares last traded at $14.39, 44.1% below their 52-week high. Over the past year the stock is up 187.2%. Net profit margin is -130.3%, below the peer median of 5.3%. Revenue grew 63.5% year over year.

Market Cap

$1.2B

Shares Out

85.3M

EPS (TTM)

—

P/E Ratio

—

P/S Ratio

9.93

P/B Ratio

2.52

Dividend / Share

—

Dividend Yield

—

52-Week High

$25.75

52-Week Low

$4.79

Volume

37,541

Avg Vol (3m)

85,468.825

Performance

+0.42%

-7.82%

-17.11%

-19.81%

YTD

-5.89%

+187.23%

Chart

Full chart →

Daily candles · volume · SMA(20)/SMA(50) · Databento EQUS.MINI.

Technicals

RSI (14)

38.49

SMA (50)

$19.16

SMA (200)

$18.52

Price vs SMA50

-24.91%

Price vs SMA200

-22.31%

ATR (14)

$1.12

Full technical analysis (26 indicators, D/W/M) →

Financials

Revenue

$124M

Net Income

$-161M

Gross Margin

—

Operating Margin

-147.0%

Net Margin

-130.3%

Return on Equity

-33.1%

Return on Assets

-23.3%

Current Ratio

10.58

Debt / Equity

0.42

Revenue Growth (YoY)

+63.5%

Latest reported annual period ending 2026-06-30 · SEC EDGAR/XBRL.

Full financials — revenue, cash flow & debt over time →

Biological Products, (No Diagnostic Substances) peers

GLUE vs 14 industry peers (Biological Products, (No Diagnostic Substances)), by market cap. Updated 16 d ago

P/S vs peers

9.93 / 19.49 med

-49% discount

Net margin vs peers

-130.3% / 5.3% med

below median

1–14 of 14


AMGN	Amgen	$240.1B	27.47	6.30	23.0%	+0.31%
GILD	Gilead Sciences	$187.5B	-57.87	6.16	-10.6%	+1.09%
MRNA	Moderna	$58.8B	-18.68	—	—	-1.94%
RVMD	Revolution Medicines, Inc.	$45.2B	-25.55	—	—	+0.76%
BIIB	Biogen	$33.1B	24.16	3.34	13.8%	+0.78%
NBIX	Neurocrine Biosciences Inc	$16.1B	22.81	4.77	20.9%	+0.33%
EXEL	Exelixis, Inc.	$14.7B	17.03	6.02	35.3%	+1.00%
HALO	Halozyme Therapeutics, Inc.	$12.6B	30.39	7.55	24.9%	+1.01%
TECH	Bio-Techne	$11.4B	62.48	9.35	15.0%	+0.21%
KRYS	Krystal Biotech, Inc.	$11.0B	45.52	24.95	54.8%	+0.58%
APGE	Apogee Therapeutics, Inc.	$10.2B	-34.57	—	—	+0.04%
KYMR	Kymera Therapeutics, Inc.	$9.7B	-32.51	—	—	-1.24%
RGEN	Repligen Corp	$9.6B	230.53	12.20	5.3%	-1.87%
PCVX	Vaxcyte, Inc.	$9.1B	-8.56	—	—	-0.62%

Source: SEC EDGAR (fundamentals/EPS/dividends) · Databento EQUS.MINI (prices) · market cap & yield computed by tradmap. Informational only — not financial advice.